616 related articles for article (PubMed ID: 20116088)
1. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
[TBL] [Abstract][Full Text] [Related]
2. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
[TBL] [Abstract][Full Text] [Related]
3. Persistent trophoblast disease following partial molar pregnancy.
Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
[TBL] [Abstract][Full Text] [Related]
4. Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2012 Feb; 124(2):250-3. PubMed ID: 22094931
[TBL] [Abstract][Full Text] [Related]
5. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.
Wolfberg AJ; Berkowitz RS; Goldstein DP; Feltmate C; Lieberman E
Obstet Gynecol; 2005 Sep; 106(3):548-52. PubMed ID: 16135585
[TBL] [Abstract][Full Text] [Related]
6. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of early-stage nonhydropic mole for diagnosis of persistent trophoblastic disease.
Miyoshi J; Ohba T; Fukunaga M; Katabuchi H
Obstet Gynecol; 2011 Oct; 118(4):847-53. PubMed ID: 21934448
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic disease.
Duc HN; van Trommel NE; Sweep FC; Massuger LF; Thomas CM
Int J Biol Markers; 2006; 21(1):45-9. PubMed ID: 16711513
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
van Trommel NE; Sweep FC; Schijf CP; Massuger LF; Thomas CM
Eur J Endocrinol; 2005 Oct; 153(4):565-75. PubMed ID: 16189178
[TBL] [Abstract][Full Text] [Related]
10. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
Franke HR; Risse EK; Kenemans P; Houx PC; Stolk JG; Vooijs GP
Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
[TBL] [Abstract][Full Text] [Related]
11. Comparison of human chorionic gonadotropin +beta and invasive trophoblast antigen disappearance rates in serum after evacuation of molar pregnancy.
Van Trommel NE; Sweep FC; Ross HA; Massuger LF; Thomas CM
Int J Mol Med; 2006 Oct; 18(4):705-11. PubMed ID: 16964426
[TBL] [Abstract][Full Text] [Related]
12. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH
Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
[TBL] [Abstract][Full Text] [Related]
13. [The serum concentration of specific beta 1-glycoprotein in trophoblastic disease].
Radikov N
Akush Ginekol (Sofiia); 1989; 28(2):15-9. PubMed ID: 2548413
[TBL] [Abstract][Full Text] [Related]
14. Guidelines following hydatidiform mole: a reappraisal.
Kerkmeijer L; Wielsma S; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):112-8. PubMed ID: 16638032
[TBL] [Abstract][Full Text] [Related]
15. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies.
Growdon WB; Wolfberg AJ; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
J Reprod Med; 2006 Nov; 51(11):871-4. PubMed ID: 17165432
[TBL] [Abstract][Full Text] [Related]
16. Persistence of gestational trophoblastic disease for longer than 1 year following evacuation of hydatidiform mole.
Elmer DB; Granai CO; Ball HG; Curry SL
Obstet Gynecol; 1993 May; 81(5 ( Pt 2)):888-90. PubMed ID: 7682320
[TBL] [Abstract][Full Text] [Related]
17. Preevacuation serum CA 125 in complete hydatidiform mole.
Tangtrakul S; Srisupandit S; Chailurkit LO; Rajatanavin R
Gynecol Oncol; 1997 Mar; 64(3):487-9. PubMed ID: 9062156
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of macrophage colony-stimulating factor in trophoblastic disease.
Kohorn EI; Kacinski BM; Stanley ER
Gynecol Oncol; 2001 Mar; 80(3):383-6. PubMed ID: 11263936
[TBL] [Abstract][Full Text] [Related]
19. Persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy.
Chen RJ; Huang SC; Chow SN; Hsieh CY; Hsu HC
Br J Obstet Gynaecol; 1994 Apr; 101(4):330-4. PubMed ID: 8199080
[TBL] [Abstract][Full Text] [Related]
20. Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve.
van Cromvoirt SM; Thomas CM; Quinn MA; McNally OM; Bekkers RL
Gynecol Oncol; 2014 Jun; 133(3):542-5. PubMed ID: 24631700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
